AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32050789
Drug: Ultrasound-guided subcostal
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided subcostal transversus abdominis plane (TAP) block with 30 mL local anesthetic (20 mL bupivacaine 0.125% plus 10 mL lidocaine 1%)
Trial: 32050789
Drug: IV analgesic
RxNorm normalized name: ANALGESIC CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV analgesic management with paracetamol 1 g
Trial: 33579199
Drug: Dexamethasone group
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone group (8 mg dexamethasone with 0.375% ropivacaine)
Trial: 32667287
Drug: Argatroban treatment
RxNorm normalized name: Argatroban
DrugBank: Argatroban (DB00278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Argatroban treatment
Trial: 33998024
Drug: Supportive periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive periodontal therapy visits (SPT) with regularity
Trial: 33998024
Drug: Supportive periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive periodontal therapy visits (SPT) with irregularity
Trial: 33998024
Drug: Supportive periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive periodontal therapy visits (SPT)
Trial: 35040869
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E supplementation (vitE), dosage not specified, duration 3 years (baseline to year 3)
Trial: 33333334
Drug: Direct oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral anticoagulants (apixaban, dabigatran, edoxaban, rivaroxaban)
Trial: 33333334
Drug: Twice-daily regimen
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily regimen of direct oral anticoagulants
Trial: 33461323
Drug: Corticosteroid (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid (40 mg methylprednisolone)
Trial: 33057367
Drug: Higher sTFR
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher sTFR or iron stores, the HFE 187C>G variant, and lower baseline hsCRP
Trial: 33852200
Drug: PRM 6
RxNorm normalized name: Pramipexole
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PRM 6 mg/day
Trial: 33852200
Drug: Low-dose PRM
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose PRM
Trial: 33852200
Drug: Higher-dose PRM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose PRM
Trial: 36309647
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of intermediate radiologist with LR radiomic model
Trial: 35721014
Drug: Real continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real continuous theta burst stimulation (cTBS) over the right cerebellar Crus I + 30-min speech-language therapy
Trial: 36339775
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate 40 mg·kg‐1 + 10 mg·kg‐1·h‐1
Trial: 36339775
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at an initial dose of 0.2 μg·kg‐1·min‐1
Trial: 34819273
Drug: Guselkumab 100
RxNorm normalized name: guselkumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab 100 mg (subcutaneous) at week 0, week 4, then every 8 weeks through week 44
Trial: 36428216
Drug: IV melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV melatonin at a daily dose of 60 mg, administered continuously for over 30 minutes starting on the day of diagnosis during a 5-day period.
Trial: 35641993
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A (BTX-A) injection in the lateral pterygoid muscle
Trial: 35352277
Drug: Carbetocin 100
RxNorm normalized name: Carbetocin 100 microgram/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbetocin 100 µg as a rapid intravenous bolus
Trial: 35352277
Drug: Carbetocin 100
RxNorm normalized name: Carbetocin 100 microgram/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbetocin 100 µg over 10 min infusion
Trial: 35352277
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (prophylactic phenylephrine infusion)
Trial: 32053567
Drug: Group Integrated
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Integrated Neurocognitive Therapy (INT)
Trial: 34184536
Drug: Site-specific labeling
RxNorm normalized name: lobeline
DrugBank: Lobeline (DB05137)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Site-specific labeling of IgG antibodies using a two-step protocol with microbial transglutaminase.
Trial: 34184536
Drug: DNA-PAINT for
RxNorm normalized name: Castellani Paint
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DNA-PAINT for labeling IgG antibodies.
Trial: 32932174
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg elemental zinc supplement
Trial: 32416145
Drug: E2 75
RxNorm normalized name: Estradiol 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 75 mcg/day
Trial: 32416145
Drug: E2 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 100 mcg/day
Trial: 32416145
Drug: E2 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 200 mcg/day
Trial: 33470769
Drug: Transdermal 17β‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17β‐estradiol (tE2, n = 21)
Trial: 33470769
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogen (n = 19)
Trial: 35508300
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine nursing intervention of burying seeds at auricular points (Control)
Trial: 36322258
Drug: Cholecalciferol supplementation
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol supplementation (daily, weekly, or monthly)
Trial: 36322258
Drug: Weekly cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly cholecalciferol supplementation
Trial: 35618446
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein shot (15 g of protein)
Trial: 33486770
Drug: 3 mg/ml
RxNorm normalized name: RNA 0.63 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/ml oligomer chitosan solution
Trial: 33486770
Drug: 6 mg/ml
RxNorm normalized name: phenol 6 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/ml oligomer chitosan solution
Trial: 33486770
Drug: 3 mg/ml
RxNorm normalized name: RNA 0.63 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/ml 30 kDa chitosan solution
Trial: 33486770
Drug: 6 mg/ml
RxNorm normalized name: phenol 6 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/ml 30 kDa chitosan solution
Trial: 33486770
Drug: Effervescent tablet
RxNorm normalized name: Pain Relief Effervescent Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effervescent tablet (Polident)
Trial: 32013621
Drug: Experimental Occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental Occupational Therapy (EOT)
Trial: 33948951
Drug: Novel scaffold
RxNorm normalized name: Viable and metabolically active allogeneic human NIKS keratinocytes and human dermal fibroblasts cellularized layered scaffold
DrugBank: Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen (DB16709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel scaffold treatment (n = 5)
Trial: 32173950
Drug: Treatment Adherence
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Adherence Programme (TAP)
Trial: 34448111
Drug: Attachment and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attachment and Biobehavioral Catch-up (ABC) intervention (10 sessions) provided as a supplement to Early Head Start (EHS)
Trial: 34703055
Drug: Modified pectoral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified pectoral nerve block (30 ml of ropivacaine 0.2%)
Trial: 36137599
Drug: Best medical
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best medical management (BMM) combined with endovascular therapy
Trial: 35805627
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of IF and SIT
Trial: 33186740
Drug: Taselisib (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taselisib (4 mg) plus fulvestrant (500 mg)
Trial: 36370124
Drug: Citalopram (add-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (add-on treatment)
Trial: 33972742
Drug: tepotinib (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tepotinib (500 mg once daily)
Trial: 34003685
Drug: Antihypertensive drug
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive drug regimen change
Trial: 35379575
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 1 g azithromycin orally on admission plus a third-generation cephalosporin intravenously for the first 48 hours, followed by amoxicillin 500 mg orally for another five days.
Trial: 32650729
Drug: Metronidazole followed
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole followed by a commercial oral/vaginal probiotic
Trial: 34673771
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) titrated based on weekly assessments, mean end-dose of 1.0 mg/kg/day
Trial: 34673771
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) titrated based on weekly assessments
Trial: 35769160
Drug: High-dose Bojungikgi-Tang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Bojungikgi-Tang (BJIGT)
Trial: 35769160
Drug: Standard-dose Bojungikgi-Tang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose Bojungikgi-Tang (BJIGT)
Trial: 35654863
Drug: Peloid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peloid therapy + home exercise
Trial: 35654863
Drug: Paraffin therapy
RxNorm normalized name: Paraffin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paraffin therapy + home exercise
Trial: 33984886
Drug: Levodopa‐carbidopa intestinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa‐carbidopa intestinal gel (LCIG) treatment
Trial: 36045304
Drug: TLPLDC + G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLPLDC + G
Trial: 34936271
Drug: Tongyuan acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongyuan acupuncture combined with medication
Trial: 34936271
Drug: Medication alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication alone (estradiol valerate tablets, 2 mg per day from the fifth day of menstruation)
Trial: 36194181
Drug: AB-506 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AB-506 at 160 mg daily for 28 days
Trial: 36194181
Drug: AB-506 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AB-506 at 400 mg daily for 28 days
Trial: 36194181
Drug: AB-506 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AB-506 at 400 mg daily for 28 days in Asian HS
Trial: 32898838
Drug: Lactoferrin, ethanol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactoferrin, ethanol, hydroxychloroquine, quaternary ammonium compounds
Trial: 32898838
Drug: Quaternary ammonium
RxNorm normalized name: Quaternary ammonium compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quaternary ammonium compounds, hydroxychloroquine
Trial: 32898838
Drug: Quaternary ammonium
RxNorm normalized name: Quaternary ammonium compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quaternary ammonium compounds, alcohol-based nasal antiseptics
Trial: 33162314
Drug: Back massage
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Back massage (15 minutes daily for four days)
Trial: 32893505
Drug: Increased loop
RxNorm normalized name: LOOP OSTOMY ROD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased loop diuretic dose
Trial: 32893505
Drug: Combination diuretic
RxNorm normalized name: atenolol and other diuretics, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination diuretic therapy (loop diuretic plus chlorothiazide)
Trial: 32893505
Drug: Standard loop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard loop diuretic therapy
Trial: 34593120
Drug: Initial triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial triple therapy (macitentan, tadalafil, and selexipag)
Trial: 34593120
Drug: Initial double
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial double therapy (macitentan, tadalafil, and placebo)
Trial: 34273682
Drug: Juçara fruit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Juçara fruit juice (JFJ) 250 mL
Trial: 32041605
Drug: Biological with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological with best practice prevention (B+P)
Trial: 32248829
Drug: Tocilizumab (subcutaneously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (subcutaneously at 162 mg/week)
Trial: 32248829
Drug: Prednisone (orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (orally at 10 mg/day)
Trial: 35193718
Drug: Brazil and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brazil and cashew nuts group (BN-Group): Energy-restricted diet containing daily 45 g of nuts (15 g of Brazil nuts + 30 g of cashew nuts), n=21
Trial: 33052965
Drug: MDMA-assisted psychotherapy
RxNorm normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA-assisted psychotherapy (MAP) consisting of 2.5 trauma-focused psychotherapy sessions and two 8-hour sessions with MDMA (mean dose of 125 mg) followed by 3.5 integration sessions
Trial: 33052965
Drug: Inactive placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive placebo or 25–40 mg of MDMA
Trial: 35166212
Drug: Trigger point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trigger point therapy (TriT)
Trial: 35166212
Drug: Acupoint therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint therapy (AcuT)
Trial: 34677153
Drug: Ozone group
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone group (received lung disinfection technique with ozone and standard COVID-19 treatment)
Trial: 34677153
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not treated with ozone, only received standard COVID-19 treatment)
Trial: 32464266
Drug: Conventional photodynamic
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional photodynamic therapy (C‐PDT)
Trial: 34838460
Drug: Bevacizumab combined
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab combined with modified FOLFOX6 (mFOLFOX6) or FOLFIRI chemotherapy
Trial: 34838460
Drug: Cetuximab combined
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab combined with modified FOLFOX6 (mFOLFOX6) or FOLFIRI chemotherapy
Trial: 33864735
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (400 μg per actuation, total dose of 1600 μg, two puffs twice per day)
Trial: 33710277
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg CBD and 5.4 mg THC daily
Trial: 33710277
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg CBD and 10.8 mg THC daily
Trial: 33710277
Drug: 360 mg
RxNorm normalized name: aspirin 360 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360 mg CBD and 16.2 mg THC daily
Trial: 33710277
Drug: 480 mg
RxNorm normalized name: magaldrate 480 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 480 mg CBD and 21.6 mg THC daily
Trial: 34329455
Drug: Alfentanil +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil + Pregabalin (300 mg orally)
Trial: 35760666
Drug: Auto-cross-linked hyaluronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auto-cross-linked hyaluronic acid gel
Trial: 33990144
Drug: Fremanezumab (monthly)
RxNorm normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fremanezumab (monthly)
Trial: 32314464
Drug: Tofogliflozin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofogliflozin (20 mg/day)
Trial: 32314464
Drug: Glimepiride (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (0.5 mg/day)
Trial: 36445874
Drug: High flavonoid
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High flavonoid pre-workout beverage (490 mg)
Trial: 36445874
Drug: Low flavonoid
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low flavonoid pre-workout beverage (5 mg)
Trial: 34980546
Drug: Calcium (500
RxNorm normalized name: calcium gluconate 45 mg calcium (500 mg) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (500 mg), Vitamin D3 (400 IU), Collagen Peptides (5 g)
Trial: 34980546
Drug: Calcium (500
RxNorm normalized name: calcium gluconate 45 mg calcium (500 mg) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (500 mg), Vitamin D3 (400 IU)
Trial: 35231887
Drug: Placebo (aluminum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (aluminum hydroxide suspension, 2.5 ml daily)
Trial: 33704919
Drug: Probenecid (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probenecid (500 mg every 6 hours)
Trial: 32589828
Drug: SAMe (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAMe (200 mg) plus Lactobacillus plantarum HEAL9 (1 × 10⁹ CFU)
Trial: 36270095
Drug: Melatonin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (20 mg once daily for five days)
Trial: 33135866
Drug: Probiotic-supplemented arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic-supplemented arm (two 4 oz. servings of the probiotic yogurt product daily)
Trial: 33064621
Drug: Music-based approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music-based approach to teach pursed-lip breathing; patients meet twice weekly for eight weeks for melodica instruction, group music-making, and COPD education.
Trial: 33542047
Drug: Colchicine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (0.5 mg thrice daily for 5 days, then 0.5 mg twice daily for 5 days)
Trial: 33453076
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D supplementation during pregnancy
Trial: 36047511
Drug: Sodium alginate
RxNorm normalized name: Sodium Alginate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium alginate 0.03 g per kg body weight per day
Trial: 36047511
Drug: Sodium alginate
RxNorm normalized name: Sodium Alginate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium alginate 0.06 g per kg body weight per day
Trial: 36047511
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg day‐1 for 60 days (positive control)
Trial: 32078063
Drug: Urinary iodine
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Urinary iodine concentration (UIC) < 100 μg/L
Trial: 32078063
Drug: Urinary iodine
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Urinary iodine concentration (UIC) 100-199 μg/L
Trial: 32078063
Drug: Urinary iodine
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Urinary iodine concentration (UIC) 200-299 μg/L
Trial: 32078063
Drug: Urinary iodine
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Urinary iodine concentration (UIC) ≥ 300 μg/L